Search Results
Sep 30, 2025, 08:45 ET eMed Population Health Appoints Dr. Dyan Hes as Chief Medical Officer
In her role, Dr. Hes will advise clinical, product and technology teams on evidence-based care models, optimizing GLP-1 therapies for diverse patient populations at scale. While strengthening partnerships with business leaders and investors, she will also work to
More news about: eMed
Sep 30, 2025, 08:00 ET todo Launches GLP-1 Friendly Protein + Fiber Shakes in a Ready-to-Drink (RTD) Format
longer. By pairing 26g of high-quality protein with 6g of prebiotic fiber, todo delivers a unique combination that naturally supports GLP-1 satiety signals while promoting gut health and sustained energy.
More news about: todo
Sep 29, 2025, 16:28 ET NVO Deadline: NVO Investors Have Opportunity to Lead Novo Nordisk A/S Securities Fraud Lawsuit
the personalization exception to the compounded GLP-1 exclusion and overstated the likelihood that such patients would switch to Novo Nordisk's branded alternatives. Further, defendants greatly overstated the potential GLP-1 market or otherwise, Novo's capability to penetrate
More news about: THE ROSEN LAW FIRM, P. A.
Sep 29, 2025, 10:56 ET Parker Waichman LLP Files Lawsuit on behalf of Georgia Resident Alleging Development of Irreversible Eye Condition, NAION, after taking Wegovy
additional cases and urges individuals who have suffered serious eye injuries after taking these widely prescribed GLP-1 receptor agonist medications to contact them for a
More news about: Parker Waichman LLP
Sep 29, 2025, 08:45 ET Novo Nordisk A/S Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm for More Information - NVO
impact of the personalization exception to the compounded GLP-1 exclusion and overstated the likelihood such patients would switch to Novo's branded alternatives, and further greatly overstated the potential GLP-1 market or otherwise Novo's capability to penetrate said markets
More news about: The Gross Law Firm
Sep 29, 2025, 08:00 ET CPDC Launches Cadena Research, a Radiopharmaceutical Preclinical CRO
development, screening, lead optimization, toxicology, dosimetry, imaging, and advanced radiochemistry capabilities. In addition, Cadena Research offers GLP capabilities for IND-enabling studies. Clients benefit from strategic advisory services offered by a team of experienced radiopharmaceutical professionals.
More news about: Centre for Probe Development and Commercialization (CPDC)
Sep 28, 2025, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Novo Nordisk A/S of Class Action Lawsuit and Upcoming Deadlines - NVO
attributed the reduction to "lowered growth expectations for the second half of 2025" for both Wegovy and Ozempic due to "the persistent use of compounded GLP-1s, slower-than-expected market expansion and competition." On this news, Novo Nordisk's American Depositary Receipt ("ADR") price
More news about: Pomerantz LLP
Sep 26, 2025, 15:27 ET Novo Nordisk A/S (NVO) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
failed to disclose to investors that: (1) Novo Nordisk repeatedly ignored and minimized the significance of the personalization exception for GLP-1 compounding, greatly overestimated its ability to capture patients coming off of compounded treatments, and was ultimately ill equipped to capitalize
More news about: Glancy Prongay & Murray LLP
Sep 26, 2025, 09:00 ET Novo Nordisk A/S Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before September 30, 2025 to Discuss Your Rights - NVO
impact of the personalization exception to the compounded GLP-1 exclusion and overstated the likelihood such patients would switch to Novo's branded alternatives, and further greatly overstated the potential GLP-1 market or otherwise Novo's capability to penetrate said markets
More news about: Levi & Korsinsky, LLP
Sep 26, 2025, 08:31 ET Survey Finds GLP-1 Users Cut Food Costs Nearly 30%
deciding to start a GLP-1 prescription, with Gen Z adults especially likely to cite financial reasons alongside health outcomes. "It's certainly the new GLP-1 economy as we call it," says Dr. Angela Tran. "On average, GLP-1s can lead to 15% or
More news about: Sunlight
Sep 26, 2025, 08:19 ET CLASS ACTION DEADLINE APPROACHING: Berger Montague Advises Novo Nordisk A/S (NYSE: NVO) Investors to Inquire About a Securities Fraud Class Action by September 30, 2025
HERE. On July 29, 2025, Novo lowered its sales and profit guidance for the second half of fiscal 2025, citing persistent use of compounded GLP-1s, slower-than-expected market expansion, and increased competition for both Wegovy® and Ozempic®. In reaction, Novo's stock price plunged from $69.00 to $53.94 per
More news about: Berger Montague
Sep 25, 2025, 08:45 ET The Gross Law Firm Notifies Shareholders of Novo Nordisk A/S(NVO) of a Class Action Lawsuit and an Upcoming Deadline
impact of the personalization exception to the compounded GLP-1 exclusion and overstated the likelihood such patients would switch to Novo's branded alternatives, and further greatly overstated the potential GLP-1 market or otherwise Novo's capability to penetrate said markets
More news about: The Gross Law Firm
Sep 24, 2025, 16:55 ET Novo Nordisk A/S (NVO) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
failed to disclose to investors that: (1) Novo Nordisk repeatedly ignored and minimized the significance of the personalization exception for GLP-1 compounding, greatly overestimated its ability to capture patients coming off of compounded treatments, and was ultimately ill equipped to capitalize
More news about: The Law Offices of Frank R. Cruz, Los Angeles
Sep 24, 2025, 10:05 ET SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Novo Nordisk
impact of the personalization exception to the compounded GLP-1 exclusion and overstated the likelihood such patients would switch to Novo's branded alternatives, and further greatly overstated the potential GLP-1 market or otherwise Novo's capability to penetrate said markets
More news about: Faruqi & Faruqi, LLP
Sep 23, 2025, 17:31 ET SGLT2 Inhibitors Market to Expand by 2034 as Companies Leverage Emerging Opportunities in Indications Such as Heart Failure, MASH, Obesity, PCOS, and Others | DelveInsight
broaden, with research extending into areas such as obesity, NASH, and PCOS. Moreover, combination regimens, linking SGLT2 inhibitors with GLP-1 receptor agonists or mineralocorticoid receptor antagonists, are gaining momentum, aiming to maximize clinical benefit while reducing adverse effects.
More news about: DelveInsight Business Research, LLP
Sep 23, 2025, 17:14 ET NVO Deadline: NVO Investors Have Opportunity to Lead Novo Nordisk A/S Securities Fraud Lawsuit
the personalization exception to the compounded GLP-1 exclusion and overstated the likelihood that such patients would switch to Novo Nordisk's branded alternatives. Further, defendants greatly overstated the potential GLP-1 market or otherwise, Novo's capability to penetrate
More news about: THE ROSEN LAW FIRM, P. A.
Sep 23, 2025, 13:00 ET Lilly plans to build a new $6.5 billion facility to manufacture active pharmaceutical ingredients in Texas
and brought online. Importantly, the site will be among those that will manufacture orforglipron, Lilly's first oral, small molecule GLP-1 receptor agonist, which the company expects to submit to global regulatory agencies for obesity by the end of this year. "Our new Houston
More news about: Eli Lilly and Company
Sep 23, 2025, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Novo Nordisk A/S of Class Action Lawsuit and Upcoming Deadlines - NVO
attributed the reduction to "lowered growth expectations for the second half of 2025" for both Wegovy and Ozempic due to "the persistent use of compounded GLP-1s, slower-than-expected market expansion and competition." On this news, Novo Nordisk's American Depositary Receipt ("ADR") price fell $15.06
More news about: Pomerantz LLP
Sep 22, 2025, 17:06 ET DEADLINE APPROACHING: Berger Montague Advises Nordisk A/S (NYSE: NVO) Investors to Inquire About a Securities Fraud Class Action by September 30, 2025
alleges that throughout the Class Period, the Company made false and misleading statements regarding the impact of compounded GLP-1 drugs. Specifically, the Company allegedly understated the effect of the FDA's personalization exception that permits many patients
More news about: Berger Montague
Sep 22, 2025, 08:45 ET Novo Nordisk A/S Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm Before September 30, 2025 to Discuss Your Rights - NVO
impact of the personalization exception to the compounded GLP-1 exclusion and overstated the likelihood such patients would switch to Novo's branded alternatives, and further greatly overstated the potential GLP-1 market or otherwise Novo's capability to penetrate said markets
More news about: The Gross Law Firm
Sep 22, 2025, 05:07 ET NVO Investors Have Opportunity to Lead Novo Nordisk A/S Securities Fraud Lawsuit with the Schall Law Firm
compounded GLP-1 exclusion on its business. The Company misstated the likelihood of patients using compounded GLP-1 switching to its name brand alternative. The Company artificially inflated its ability to achieve continued growth in the GLP-1 market. Based on these
More news about: The Schall Law Firm
Sep 21, 2025, 20:10 ET Ascletis Announces ASC47 in Combination with Semaglutide Demonstrated Up to 56.2% Greater Relative Reduction in Body Weight in Participants with Obesity Compared to Semaglutide Monotherapy
a once-monthly subcutaneously administered GLP-1 receptor (GLP-1R)/GIP-receptor (GIPR) peptide agonist, and once-daily oral version of ASC47 in combination with once-daily oral ASC30. ASC35 is an in-house discovered and developed GLP-1R/GIPR peptide agonist. The pharmacokinetic data
More news about: Ascletis Pharma Inc.
Sep 19, 2025, 08:45 ET Investors who lost money on Novo Nordisk A/S(NVO) should contact Levi & Korsinsky about pending Class Action - NVO
impact of the personalization exception to the compounded GLP-1 exclusion and overstated the likelihood such patients would switch to Novo's branded alternatives, and further greatly overstated the potential GLP-1 market or otherwise Novo's capability to penetrate said markets
More news about: Levi & Korsinsky, LLP
Sep 19, 2025, 06:01 ET Innovent Announces Mazdutide Received Approval from China's NMPA for Glycemic Control in Adults with Type 2 Diabetes
mazdutide, a first-in-class dual glucagon (GCG)/glucagon-like peptide-1 (GLP-1) receptor agonist, for glycemic control in adults with type 2 diabetes (T2D). Mazdutide is the world's first dual GCG/GLP-1 receptor agonist approved for glycemic control in adults with T2D. It is
More news about: Innovent Biologics
Sep 19, 2025, 06:00 ET Orforgliprona, GLP-1 oral da Lilly, demonstra perda de peso significativa e melhorias cardiometabólicas nos resultados completos do ATTAIN-1, publicados no The New England Journal of Medicine
estudo ATTAIN-1, no qual foram avaliadas a segurança e a eficácia de orforgliprona, um agonista oral do receptor do peptídeo-1 semelhante ao glucacon (GLP-1) experimental, em adultos com obesidade ou com sobrepeso associado a uma comorbidade relacionada ao peso, e sem diabetes. Na semana 72, todas as três
More news about: Eli Lilly do Brasil